---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205117"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:14:04.782054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook

## Summary
- Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.
- Net loss $(10.8M) ($0.16/shr) vs $(12.7M) loss a year ago; operating expenses down 6% to $25.1M.
- Cash $19.0M (incl. $5.8M restricted); made $5M debt principal payment in March to reduce debt.
- Optum/UHC/UBH expanded TMS policy to allow nurse practitioners to order/administer NeuroStar, covering 34.8M lives across 26 states.
- FY2026 guidance: revenue $160-166M, gross margin 47-49%, op ex $100-105M, cash from ops negative $13-17M.

## SEC filing metadata
- accession: 0001193125-26-205117
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312526205117/0001193125-26-205117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312526205117/d139145d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205117
- JSON: https://secwatch.observer/filing/0001193125-26-205117.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205117.txt

## Source-grounded claims
- claim_id: 9febbb37f58ebd63f3b29ae3d1247f7d73f6e19a
  claim: Neuronetics, Inc. reported three months ended March 31, 2026 results: revenue $34.5 million, net income $(10.8) million, EPS $(0.16) per share. Guidance reaffirmed.
  evidence_excerpt: Total revenue for the three months ended March 31, 2026 was $34.5 million, an increase of $2.5 million, or 8%, compared to the three months ended March 31, 2025 revenue of $32.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000119312526205117/0001193125-26-205117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.